Jill Badik, DO
Family Medicine · Fostoria, OHNPI 1568649069
Payments from drug & device makers
Across 75 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$170
- AbbVie$159
- Phathom Pharmaceuticals, Inc.$107
- Pfizer$104
- Boehringer Ingelheim$100
- Lilly USA, LLC$84
- plus $623 from 20 others
What the payments were for
- Food & beverage$1,341100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $170 |
| AbbVie(2 entities) | 9 | $159 |
| Phathom Pharmaceuticals, Inc. | 3 | $107 |
| Pfizer | 6 | $104 |
| Boehringer Ingelheim | 6 | $100 |
| Lilly USA, LLC | 6 | $84 |
| Merck | 4 | $62 |
| Novo Nordisk | 4 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Kowa Pharmaceuticals America, Inc. | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Johnson & Johnson | 2 | $45 |
| Abbott | 2 | $40 |
| Dexcom, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Amgen | 2 | $25 |
| Novartis | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Vertex | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $13 |
How this compares
$1,347 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 173 | $97,995 |
| JardianceEmpagliflozin | 88 | $88,148 |
| MounjaroTirzepatide | 45 | $47,320 |
| TrulicityDulaglutide | 27 | $28,871 |
| JanuviaSitagliptin Phosphate | 30 | $28,729 |
| XareltoRivaroxaban | 38 | $25,154 |
| OzempicSemaglutide | 24 | $24,765 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $22,868 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 64 | $19,969 |
| FarxigaDapagliflozin Propanediol | 12 | $16,692 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $16,161 |
| EntrestoSacubitril/Valsartan | 12 | $14,877 |
| Spiriva RespimatTiotropium Bromide | 13 | $10,894 |
| MovantikNaloxegol Oxalate | 19 | $7,505 |
| NamzaricMemantine Hcl/Donepezil Hcl | 14 | $7,484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $100 | $99,042101 claims |
| PfizerEliquis | $104 | $97,995173 claims |
| Lilly USA, LLCMounjaro, Trulicity | $84 | $76,19172 claims |
| MerckJanuvia | $62 | $28,72930 claims |
| Johnson & JohnsonXarelto | $45 | $25,15438 claims |
| Novo NordiskOzempic | $61 | $24,76524 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $14 | $21,94324 claims |
| AstraZenecaFarxiga | $170 | $16,69212 claims |
| NovartisEntresto | $21 | $14,87712 claims |
| AbbVieNamzaric | $159 | $7,48414 claims |
| Sanofi-aventis U.S. LLCLantus | $16 | $2,59437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Fostoria
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.